Literature DB >> 10716758

An overexpression of fibroblast growth factor (FGF) and FGF receptor 4 in a severe clinical phenotype of facioscapulohumeral muscular dystrophy.

A Saito1, I Higuchi, M Nakagawa, M Saito, Y Uchida, M Inose, T Kasai, T Niiyama, H Fukunaga, K Arimura, M Osame.   

Abstract

We evaluated the expression of a select panel of growth factors and their receptors, including fibroblast growth factor 1 (FGF-1), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), FGF receptor 1 (FGF-R1), FGF receptor 3 (FGF-R3), FGF receptor 4 (FGF-R4), PDGF receptor alpha (PDGF-Ralpha), PDGF receptor beta (PDGF-Rbeta), and heparan sulfate proteoglycan (HSPG), in muscle biopsy specimens from nine facioscapulohumeral muscular dystrophy (FSHD) patients using immunohistochemistry. Two cases of Duchenne-type muscular dystrophy (DMD), two of Becker-type muscular dystrophy (BMD), and one of limb-girdle-type muscular dystrophy (LGMD) were also investigated. Widespread immunostaining for FGF-1 and FGF-2 on the sarcolemma and overexpression of FGF-R4 in endomysial and perimysial connective tissue were seen in one patient with a severe clinical phenotype of FSHD who had respiratory failure. Standard histochemistry in this patient revealed marked interstitial fibrosis and lobulated fibers. The overexpression of FGF and FGF-R4 in this severe FSHD case may be associated with the muscle fibrosis and disease severity. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10716758     DOI: 10.1002/(sici)1097-4598(200004)23:4<490::aid-mus6>3.0.co;2-k

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Activated EGL-15 FGF receptor promotes protein degradation in muscles of Caenorhabditis elegans.

Authors:  Nathaniel J Szewczyk; Lewis A Jacobson
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

Review 2.  Deciphering transcription dysregulation in FSH muscular dystrophy.

Authors:  Melanie Ehrlich; Michelle Lacey
Journal:  J Hum Genet       Date:  2012-06-21       Impact factor: 3.172

3.  Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.

Authors:  Caroline Conte; Nadera Ainaoui; Aurélie Delluc-Clavières; Marie P Khoury; Rania Azar; Françoise Pujol; Yvan Martineau; Stéphane Pyronnet; Anne-Catherine Prats
Journal:  Nucleic Acids Res       Date:  2009-06-26       Impact factor: 16.971

4.  1,25(OH)(2)vitamin D(3) enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C(2)C(12) skeletal muscle cells.

Authors:  Leah A Garcia; Monica G Ferrini; Keith C Norris; Jorge N Artaza
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-12       Impact factor: 4.292

Review 5.  Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy.

Authors:  Christine Péladeau; Bernard J Jasmin
Journal:  RNA Biol       Date:  2020-11-19       Impact factor: 4.652

6.  An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed.

Authors:  Bruce F Smith; Yongping Yue; Philip R Woods; Joe N Kornegay; Jin-Hong Shin; Regina R Williams; Dongsheng Duan
Journal:  Lab Invest       Date:  2010-08-16       Impact factor: 5.662

Review 7.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

8.  FGFR1 inhibits skeletal muscle atrophy associated with hindlimb suspension.

Authors:  John Eash; Aaron Olsen; Gert Breur; Dave Gerrard; Kevin Hannon
Journal:  BMC Musculoskelet Disord       Date:  2007-04-10       Impact factor: 2.362

Review 9.  Stem cell transplantation for muscular dystrophy: the challenge of immune response.

Authors:  Sara Martina Maffioletti; Maddalena Noviello; Karen English; Francesco Saverio Tedesco
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.